Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Net Cash Flow (2020 - 2025)

Rani Therapeutics Holdings (RANI) has 6 years of Net Cash Flow data on record, last reported at -$6.1 million in Q3 2025.

  • For Q3 2025, Net Cash Flow fell 2481.01% year-over-year to -$6.1 million; the TTM value through Sep 2025 reached -$133000.0, up 80.86%, while the annual FY2024 figure was -$2.1 million, 90.06% up from the prior year.
  • Net Cash Flow reached -$6.1 million in Q3 2025 per RANI's latest filing, down from $150000.0 in the prior quarter.
  • Across five years, Net Cash Flow topped out at $60.4 million in Q3 2021 and bottomed at -$69.5 million in Q3 2022.
  • Average Net Cash Flow over 5 years is -$3.6 million, with a median of -$2.4 million recorded in 2024.
  • Peak YoY movement for Net Cash Flow: soared 1651.06% in 2021, then crashed 2481.01% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at -$12.3 million in 2021, then soared by 98.28% to -$212000.0 in 2022, then soared by 520.75% to $892000.0 in 2023, then crashed by 157.74% to -$515000.0 in 2024, then plummeted by 1087.77% to -$6.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were -$6.1 million in Q3 2025, $150000.0 in Q2 2025, and $6.3 million in Q1 2025.